Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy
Conditions
Keywords
merkel cell carcinoma, sentinel lymph node, PD-1 antibody, skin cancer, Cemiplimab, MCC
Brief summary
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Interventions
DRUGCemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
DRUGPlacebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.
Sponsors
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany
Universität Duisburg-Essen
Regeneron Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient has signed informed written consent. 2. Patients is 18 years and older at time of signing of written informed consent 3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending. 4. Patient has ECOG performance status 0-2. 5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters. 1. Absolute number of neutrophils ≥ 1.5 x 109/L 2. Platelets ≥ 75 x 109/L 3. Hemoglobin ≥ 9 g/dL 4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert) 5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN 6. AP ≤ 2.5x ULN 7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min 6. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy. 7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
1. Patient has prior sentinel lymph node removal for the current MCC. 2. Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies) 3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not. 4. Patient had prior organ transplantation including allogenic stem-cell transplantation. 5. Patient receives immunosuppressive concomitant medication, EXCEPT for the following: i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection). ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent. iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication). 6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein. 7. Patient has active autoimmune or inflammatory disorders. 8. Patient has history of interstitial lung disease. 9. Patient has active infection requiring systemic therapy. 10. Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency. NOTE: Patients are eligible if: * Patients have controlled HIV infection with CD4 counts is \> 350 cells/μL and viral load is undetectable \[HIV RNA PCR\]. Patients with controlled HIV infection must be monitored per local standards during the trial. * Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load \[HBV DNA PCR\]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab. * Patients positive for HCV antibody have controlled HCV infection with undetectable viral load \[HCV RNA PCR\]. 11. Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial 12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment. 13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results. 14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results 15. Patient is legally incapacitated or has limited legal capacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nodal micrometastases-free rate | up to 36 months | rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | up to 66 months | time from randomization until date of the first of the following events: MCC progression, MCC recurrence, and MCC-related death |
| Overall survival | up to 66 months | time from randomization until date of death from any cause |
| Disease specific survival | up to 66 months | time from randomization until date of MCC-related death |
| Quality of life using FCRI-SF questionnaire | up to 66 months | Quality of life determined using the FCRI-SF questionnaire |
| Safety (AEs and SAEs) | up to 66 months | incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
| Quality of life using the mFACT-M questionnaire | up to 66 months | Quality of life determined using the mFACT-M questionnaire |
Countries
Germany
Contacts
CONTACTRalf Gutzmer, Prof. Dr. med.
CONTACTMichelle Tez
STUDY_DIRECTORSalah Al-Batran, Prof. Dr.
Institut für Klinische Krebsforschung IKF GmbH
PRINCIPAL_INVESTIGATORRalf Gutzmer, Prof. Dr. med.
Johannes Wesling Klinikum Minden
PRINCIPAL_INVESTIGATORJuergen C. Becker, Prof. Dr. Dr.
Translational Skin Cancer Research University Duisburg-Essen, Germany
Outcome results
None listed